Company Description
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Country | United States |
IPO Date | Dec 21, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 5 |
CEO | Thomas H. Jensen |
Contact Details
Address: 210 Broadway Cambridge, Massachusetts United States | |
Website | https://www.allarity.com |
Stock Details
Ticker Symbol | ALLR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001860657 |
CUSIP Number | 016744104 |
ISIN Number | US0167443029 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Thomas H. Jensen | Founder, Chief Executive Officer & Director |
Alexander Epshinsky | Chief Financial Officer |
Dr. Jeremy R. Graff Ph.D. | President & Chief Development Officer |
Dr. Jose L. Iglesias M.D. | Consultant Chief Medical Officer |
Dr. Steen Meier Knudsen Ph.D. | Founder & Chief Scientific Officer |
Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. | Co-Founder |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 19, 2024 | 8-K | Current Report |
Nov 14, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | 8-K | Current Report |
Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 23, 2024 | 8-K | Current Report |
Oct 11, 2024 | 8-K | Current Report |
Oct 04, 2024 | 8-K | Current Report |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 3 | Filing |
Sep 18, 2024 | 3 | Filing |